BioNTech SE (BNTX)
87.46
-0.98
(-1.11%)
USD |
NASDAQ |
Jun 18, 10:07
BioNTech Cash from Financing (Quarterly): -8.472M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -8.472M |
| December 31, 2023 | -9.236M |
| September 30, 2023 | -337.86M |
| June 30, 2023 | -182.95M |
| March 31, 2023 | -312.87M |
| December 31, 2022 | -132.20M |
| September 30, 2022 | -617.69M |
| June 30, 2022 | -837.00M |
| March 31, 2022 | 90.11M |
| December 31, 2021 | -57.27M |
| September 30, 2021 | -10.13M |
| Date | Value |
|---|---|
| June 30, 2021 | 184.27M |
| March 31, 2021 | -5.423M |
| December 31, 2020 | 111.51M |
| September 30, 2020 | 747.05M |
| June 30, 2020 | 161.01M |
| March 31, 2020 | 2.207M |
| December 31, 2019 | 146.98M |
| September 30, 2019 | 276.59M |
| June 30, 2019 | 4.437M |
| March 31, 2019 | 1.089M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-837.00M
Minimum
Jun 2022
747.05M
Maximum
Sep 2020
-39.35M
Average
-6.947M
Median
Cash from Financing (Quarterly) Benchmarks
| Pfizer Inc | -4.931B |
| Moderna Inc | 14.00M |
| GSK PLC | -1.344B |
| Cellectis SA | 11.90M |
| Biodexa Pharmaceuticals Plc | -- |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -344.65M |
| Cash from Investing (Quarterly) | -2.503B |
| Free Cash Flow | 5.344B |
| Free Cash Flow Per Share (Quarterly) | -2.051 |
| Free Cash Flow to Equity (Quarterly) | -506.34M |
| Free Cash Flow to Firm (Quarterly) | -493.35M |
| Free Cash Flow Yield | 25.42% |